The Latest Cannabis Articles from Streetwise Reports
Compared to the previous year, the company's overall operating results for the quarter are better, noted a Noble Capital Markets report.
The company is expected to outperform again in 2022 given its focus on strategic growth and acquisitions, noted a Noble Capital Markets report.
Technical analyst Clive Maund explains why he rates this company a strong speculative buy.
Despite a dampened Q1 FY22 performance and an uncertain future, parts of a cannabis firm's story remain attractive, warranting a Market Perform rating, noted a Noble Capital Markets report.
Whereas U.S. multistate cannabis operators are expected to do well in 2022, federal legalization of cannabis would give a jolt to companies of all sizes, noted a ROTH Capital Partners report.
Showing Results: 1 to 5 of 5